Business, energy, technology, markets and global industry news from Business News Today

Cynthia Levy

PharmaDeviceNews Cynthia Levy
Representative image of liver disease drug research and clinical data analysis. Zydus’ FDA Priority Review for saroglitazar highlights the growing treatment competition in primary biliary cholangitis.
Pharma & Biotech

Gilead Sciences’ Livdelzi achieves 75% ALP normalisation response in Phase 3 IDEAL trial

Gilead's Livdelzi achieved 75.4% ALP normalisation in Phase 3 IDEAL versus 16.1% with placebo. Examine its clinical and regulatory impact.

Read More